Lakefront Biotherapeutics (GLPGF) Capital Expenditures (QoQ) (2016 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Capital Expenditures (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 92.29% |
| Dec 31, 2025 | 43.96% |
| Sep 30, 2025 | 29.16% |
| Jun 30, 2025 | 12.24% |
| Mar 31, 2025 | 7.47% |
| Dec 31, 2024 | -24.44% |
| Sep 30, 2024 | -30.18% |
| Jun 30, 2024 | 12.05% |
| Mar 31, 2024 | 79.80% |
| Mar 31, 2023 | 83.62% |
| Mar 31, 2022 | 83.39% |
| Jun 30, 2021 | -28.51% |
| Mar 31, 2021 | 79.81% |
| Jun 30, 2020 | -120.75% |
| Mar 31, 2020 | 87.23% |
| Dec 31, 2019 | -81.20% |
| Sep 30, 2019 | -315.35% |
| Jun 30, 2019 | -37.73% |
| Mar 31, 2019 | 79.85% |
| Dec 31, 2018 | -711.93% |